Company History

  • August 2013

    China Biologic repurchased 1,479,704 shares of common stock from one of its individual shareholders for a consideration of $29,594,080.
  • July 2013

    Guizhou Taibang received manufacturing approval certificate for Human Prothrombin Complex Concentrate ("PCC") from China Food and Drug Administration (“CFDA”).
  • June 2013

    Shandong Taibang received the renewed Good Manufacturing Practice ("GMP") certification from China Food and Drug Administration ("CFDA") in respect of its updated plasma production facility.
  • April 2013

    Shandong Taibang’s newly built plasma collection station in Cao Xian county obtained plasma collection license from the Shandong Provincial Health Department and commenced commercial plasma collection.
FirstPage | PreviousPage | NextPage | LastPage CurrentPageIndex:3 [1] [2] [3] [4] [5] [6] [7] 
© 2014 China Biologic Products, Inc. All Rights Reserved.